SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
37.14
+0.33 (0.90%)
At close: Dec 26, 2024, 4:00 PM
37.17
+0.03 (0.08%)
After-hours: Dec 26, 2024, 5:43 PM EST
SpringWorks Therapeutics Revenue
SpringWorks Therapeutics had revenue of $49.30M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $135.49M. In the year 2023, SpringWorks Therapeutics had annual revenue of $5.45M.
Revenue (ttm)
$135.49M
Revenue Growth
n/a
P/S Ratio
19.70
Revenue / Employee
$444,220
Employees
305
Market Cap
2.76B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 9.47B |
Patterson Companies | 6.55B |
Surgery Partners | 2.99B |
Amedisys | 2.32B |
LifeStance Health Group | 1.21B |
Neogen | 912.20M |
iRhythm Technologies | 560.03M |
SWTX News
- 11 days ago - Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
- 4 weeks ago - SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewsWire
- 6 weeks ago - SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
- 6 weeks ago - SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting - GlobeNewsWire
- 6 weeks ago - SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology - GlobeNewsWire
- 7 weeks ago - SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting - GlobeNewsWire